Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management

Cited by (1,000)

Items 801–900 of 1,000

1. The role of capsule endoscopy in assessing mucosal inflammation in ulcerative colitis
   Hai Yun Shi, Siew C. Ng, Kelvin Kam‐Fai Tsoi, Justin CY Wu, Joseph J.�Y. Sung, Francis K.L. Chan · 2014 · Expert Review of Gastroenterology & Hepatology
2. Diagnostic imaging advances in murine models of colitis
   Markus Brückner · 2016 · World Journal of Gastroenterology
3. French national consensus clinical guidelines for the management of ulcerative colitis
   Laurent Peyrin‐Biroulet, Yoram Bouhnik, Xavier Roblin, Guillaume Bonnaud, Hervé Hagège, Xavier Hébuterne · 2016 · Digestive and Liver Disease
4. How to Differentiate Segmental Colitis Associated With Diverticulosis and Inflammatory Bowel Diseases
   Claudio Cassieri, Giovanni Brandimarte, Walter Elisei, G Lecca, Elisabetta Goni, Antônio Penna, Marcello Picchio, Antonio Tursi · 2016 · Journal of Clinical Gastroenterology
5. Surgical management of inflammatory bowel disease in China: a systematic review of two decades
   Qiao Yu, Ren Mao, Lei Lian, Siew C. Ng, Shenghong Zhang, Zhihui Chen, Yanyan Zhang, Yun Qiu, Baili Chen, Yao He et al. · 2016 · Intestinal Research
6. Emerging treatments for ulcerative colitis: a systematic review
   Damianos G. Kokkinidis, Eftychia E. Bosdelekidou, Sotiria Maria Iliopoulou, Alexandros G. Tassos, Pavlos Texakalidis, Konstantinos P. Economopoulos, Antonis A. Kousoulis · 2017 · Scandinavian Journal of Gastroenterology
7. Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn’s disease
   Arne Carlsen, Roald Omdal, Kristian Leitao, Kjetil Isaksen, Anne Kristine Hetta, Lars Normann Karlsen, Lars Aabakken, Nils Bolstad, David John Warren, Knut E. A. Lundin et al. · 2018 · Therapeutic Advances in Gastroenterology
8. Nonbiological therapeutic management of ulcerative colitis
   Nicolò Mezzina, Sophia Elizabeth Campbell Davies, Sandro Ardizzone · 2018 · Expert Opinion on Pharmacotherapy
9. Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis
   Fabrizio Bossa, Giuseppe Biscaglia, Maria Rosa Valvano, Giuseppe Costantino, Angelo Lauria, Rocco Clemente, Concetta Ferracane, Endrit Shahini, Marco Mendolaro, Laurino Grossi et al. · 2019 · Digestive Diseases and Sciences
10. Effects of Antibiotic Pretreatment of an Ulcerative Colitis-Derived Fecal Microbial Community on the Integration of Therapeutic Bacteria In Vitro
    Kaitlyn Oliphant, Kyla Cochrane, Kathleen Schroeter, Michelle C. Daigneault, Sandi Yen, Elena Francisca Verdu, Emma Allen‐Vercoe · 2020 · mSystems
11. Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1
    Edward V. Loftus, Bruce E. Sands, Jean‐Frédéric Colombel, Iris Dotan, Javaria Mona Khalid, David Tudor, Parnia Geransar · 2020 · Clinical and Experimental Gastroenterology
12. Medical therapy versus surgery in moderate-to-severe ulcerative colitis
    Gionata Fiorino, Silvio Danese, Giovanni Giacobazzi, Antonino Spinelli · 2020 · Digestive and Liver Disease
13. A Comprehensive Review of Topical Therapies for Distal Ulcerative Colitis.
    Russell D. Cohen, Roni Weisshof · 2020 · PubMed Central
14. Novel Approaches Identifying Relevant Patient-Reported Outcomes in Patients With Inflammatory Bowel Diseases—LISTEN 1
    Niels Teich, H Schulze, Jana Knop, Michael Obermeier, Andreas Stallmach · 2021 · Crohn s & Colitis 360
15. Protective mechanisms of Agrimonia pilosa Ledeb in dextran sodium sulfate-induced colitis as determined by a network pharmacology approach
    Chen Li, Meng Wang, Junkang Sui, Yongkun Zhou, Wei Chen · 2021 · Acta Biochimica et Biophysica Sinica
16. Increased SERPINA3 Level Is Associated with Ulcerative Colitis
    Jingwei Zhang, Wei Wang, Shenglong Zhu, Yong Q. Chen · 2021 · Diagnostics
17. Relationship Between Patient Sex and Serum Tumor Necrosis Factor Antagonist Drug and Anti-drug Antibody Concentrations in Inflammatory Bowel Disease; A Nationwide Cohort Study
    Mohammad Shehab, Hajer Alasfour, Israa Abdullah, Ghadeer Alhendi, Anwar Alhadab, Ahmad Alfadhli, Ali H. Ziyab, Robert J. Battat · 2021 · Frontiers in Medicine
18. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study
    Li Ji, Zhanju Liu, P. Hu, Zhonghui Wen, Qian Cao, Xiaoping Zou, Yan Chen, Ying-De Wang, Jie Zhong, Xizhong Shen et al. · 2022 · BMC Gastroenterology
19. Dehydrocostus Lactone Suppresses Dextran Sulfate Sodium-Induced Colitis by Targeting the IKKα/β-NF-κB and Keap1-Nrf2 Signalling Pathways
    Yun Yuan, Qiongying Hu, Lu Liu, Fan Xie, Luyao Yang, Yuchen Li, Chuantao Zhang, Hongqing Chen, Jianyuan Tang, Xiaofei Shen · 2022 · Frontiers in Pharmacology
20. Medication Adherence and Its Influencing Factors Among Inflammatory Bowel Disease Patients in China
    Fen Liang Xu, Juping Tang, Zhiping Zhu, Yan Chen, Wen Hu, Sha Lu, Yunxian Zhou, Ding Lin · 2022 · International Journal of General Medicine
21. Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal
    Anita Annaházi, Tamás Molnár · 2015 · Gastroenterology Research and Practice
22. The use of oral corticosteroids in inflammatory bowel diseases in Italy: An IG-IBD survey
    Federica Fascì-Spurio, Gianmichele Meucci, Claudio Papi, Simone Saibeni · 2017 · Digestive and Liver Disease
23. The non-drug costs associated with the administration of an intravenous biologic treatment in the hospital setting
    Jodi Cronin, Stephen Moore, Niamh Lenihan, Marion O’Shea, Noel Woods · 2018 · Irish Journal of Medical Science (1971 -)
24. Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center
    Jason Reinglas, Lóránt Gönczi, Christine Verdon, Talat Bessissow, Waqqas Afif, Gary Wild, Ernest Gerald Seidman, Alain Bitton, Peter Laszlo Lakatos · 2019 · Digestive Diseases and Sciences
25. Budesonide MMX®: A Review of Its Use in Patients with Mild to Moderate Ulcerative Colitis
    Sheridan M. Hoy · 2015 · Drugs
26. Metabolomics facilitate the personalized management in inflammatory bowel disease
    Rirong Chen, Jieqi Zheng, Li Li, Chao Li, Kang Chao, Zhirong Zeng, Minhu Chen, Shenghong Zhang · 2021 · Therapeutic Advances in Gastroenterology
27. Hedysarum multijugum Maxim treats ulcerative colitis through the PI3K-AKT and TNF signaling pathway according to network pharmacology and molecular docking
    Zihao Zhang, Wei Chong, Xiaozhou Xie, Yuan Liu, Liang Shang, Leping Li · 2022 · Annals of Translational Medicine
28. Ustekinumab is associated with superior treatment persistence but not with higher remission rates versus vedolizumab in patients with refractory Crohn’s disease: results from a multicentre cohort study
    Péter Bacsúr, Mária Matúz, Tamás Resál, Pál Miheller, Tamas Szamosi, Eszter Schäfer, Patrícia Sarlós, Ákos Iliás, Kata Judit Szántó, Mariann Rutka et al. · 2022 · Therapeutic Advances in Gastroenterology
29. Integrated Network Pharmacology, Molecular Docking and Animal Experiment to Explore the Efficacy and Potential Mechanism of Baiyu Decoction Against Ulcerative Colitis by Enema
    Yuan Cui, Jingyi Hu, Yanan Li, Ryan Au, Yulai Fang, Cheng Cheng, Feng Xu, Weiyang Li, Yuguang Wu, Lei Zhu et al. · 2023 · Drug Design Development and Therapy
30. The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease
    Taha Qazi, Bhavesh Shah, Mohammed El-Dib, Francis A. Farraye · 2015 · Digestive Diseases and Sciences
31. Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study
    Haruhiko Ogata, Nobuo Aoyama, Seiichi Mizushima, Atsushi Hagino, Toshifumi Hibi∥ · 2017 · Intestinal Research
32. Risk Factors and Clinical Outcomes of Head and Neck Cancer in Inflammatory Bowel Disease: A Nationwide Cohort Study
    Loes H.C. Nissen, Lauranne A. A. P. Derikx, A Jacobs, Carla ML van Herpen, Wietske Kievit, Rob H.A. Verhoeven, Esther C. van den Broek, Elise M. Bekers, Tim R. A. van den Heuvel, Marieke J. Pierik et al. · 2018 · Inflammatory Bowel Diseases
33. Effectiveness and Nephrotoxicity of Long-Term Tacrolimus Administration in Patients with Ulcerative Colitis
    Keiichi Haga, Tomoyoshi Shibuya, Kei Nomura, Koki Okahara, Osamu Nomura, Dai Ishikawa, Naoto Sakamoto, Taro Osada, Akihito Nagahara · 2020 · Journal of Clinical Medicine
34. Impact of BMGIM Music Therapy on Emotional State in Patients with Inflammatory Bowel Disease: A Randomized Controlled Trial
    Vicente Alejandro March-Luján, Vicente Prado‐Gascó, José María Huguet, Xavier Cortés, José María Paredes Arquiola, María Capilla-Igual, María Josefa-Rodríguez-Morales, Ana Monzó, José Luis Platero Armero, José Enrique de la Rubia Ortí · 2021 · Journal of Clinical Medicine
35. Association between antidepressant medication use and steroid dependency in patients with ulcerative colitis: a population-based study
    Jonathan Blackwell, Christopher Alexakis, Sonia K Saxena, Hanna Creese, Alex Bottle, Irene Petersen, Matthew H. Hotopf, Richard Pollok · 2021 · BMJ Open Gastroenterology
36. Chronic Intestinal Disorders in Humans and Pets: Current Management and the Potential of Nutraceutical Antioxidants as Alternatives
    Giorgia Meineri, Elisa Martello, E. Radice, Natascia Bruni, Vittorio Saettone, David Atuahene, Angelo Armandi, Giulia Testa, Davide Giuseppe Ribaldone · 2022 · Animals
37. Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study
    Edward V. Loftus, Séverine Vermeire, Brian G. Feagan, Franck‐Olivier Le Brun, Alessandra Faria Oortwijn, Ulrik Moerch, William J. Sandborn, Toshifumi Hibi∥ · 2022 · Journal of Crohn s and Colitis
38. Nicotinamide adenine dinucleotide metabolism: driving or counterbalancing inflammatory bowel disease?
    Xinru Xue, Yumeng Miao, Zhifeng Wei · 2022 · FEBS Letters
39. Exploring & exploiting our ‘other self’ – Does the microbiota hold the key to the future therapy in Crohn's?
    Lea-Maxie Haag, Britta Siegmund · 2014 · Best Practice & Research Clinical Gastroenterology
40. Patient-relevant Endpoints in Inflammatory Bowel Diseases - Have Changes Occurred in Germany over the Past Twelve Years?
    Andreas Stallmach, Ulf Dennler, Ursula Marschall, Carsten Schmidt · 2015 · Journal of Crohn s and Colitis
41. Practical Approaches to “Top–Down” Therapies for Crohn’s Disease
    Aranzazu Jauregui-Amezaga, Gert Van Assche · 2016 · Current Gastroenterology Reports
42. Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial
    Axel U Dignass, Robert Schnabel, Jacek A. Romatowski, V. V. Pavlenko, Andrey E. Dorofeyev, Jeļena Derova, Laimas Virginijus Jonaitis, Karin Dilger, Tanju Nacak, Roland Greinwald et al. · 2017 · United European Gastroenterology Journal
43. BCL-2 levels do not predict azathioprine treatment response in inflammatory bowel disease, but inhibition induces lymphocyte apoptosis and ameliorates colitis in mice
    Bruce Weder, M Mozaffari, Luc Biedermann, Céline Mamie, Anja Moncsek, Longcheng Wang, S H Clarke, Gerhard Rogler, Bradford L. McRae, Candace L. Graff et al. · 2018 · Clinical & Experimental Immunology
44. Recurrent mesalazine-induced myopericarditis in a patient with ulcerative colitis
    Teresa Dias, Arsénio Santos, Rui Marques dos Santos, Armando de Mattos Carvalho · 2019 · BMJ Case Reports
45. Rate of Adverse Events and Associated Health Care Costs for the Management of Inflammatory Bowel Disease in Germany
    Thomas Wilke, Antje Groth, Gráinne H. Long, Amanda R. Tatro, Diana K. Sun · 2019 · Clinical Therapeutics
46. Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study
    Joo Hye Song, Eun Ae Kang, Soo‐Kyung Park, Sung Noh Hong, You Sun Kim, Ki Bae Bang, Kyeong Ok Kim, Hong Sub Lee, Sang‐Bum Kang, Seung Yong Shin et al. · 2021 · Gut and Liver
47. Drug Repositioning in Inflammatory Bowel Disease Based on Genetic Information
    Valerie Collij, Eleonora Anna Margaretha Festen, Rudi Alberts, Rinse Karel Weersma · 2016 · Inflammatory Bowel Diseases
48. Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety
    Giovanni Maconi, Deborah Camatta, Rosanna Cannatelli, Francesca Ferretti, Anna Maria Carvalhas Gabrielli, Sandro Ardizzone · 2021 · Therapeutics and Clinical Risk Management
49. Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada
    Elisabetta Fenu, Vasily Lukyanov, Annabel Acs, Xenia Radu, Stephanie Stypa, Aren Fischer, John Kenneth Marshall, Mark Oppe · 2022 · PharmacoEconomics - Open
50. Thiopurine S-Methyltransferase Polymorphisms Predict Hepatotoxicity in Azathioprine-Treated Patients with Autoimmune Diseases
    Heh-Shiang Sheu, Yi‐Ming Chen, Yi‐Ju Liao, Chia‐Yi Wei, Junpeng Chen, Hsueh‐Ju Lin, Wei‐Ting Hung, Wen‐Nan Huang, Yi‐Hsing Chen · 2022 · Journal of Personalized Medicine
51. (-)-Fenchone Prevents Cysteamine-Induced Duodenal Ulcers and Accelerates Healing Promoting Re-Epithelialization of Gastric Ulcers in Rats via Antioxidant and Immunomodulatory Mechanisms
    Maria Elaine Cristina Araruna, Edvaldo Balbino Alves Júnior, Catarina Alves de Lima Serafim, Matheus Marley Bezerra Pessoa, Michelle Liz de Souza Pessôa, Vitória Pereira Alves, Marcelo Sobral da Silva, Marianna Vieira Sobral, Adriano Francisco Alves, Mayara Karla dos Santos Nunes et al. · 2024 · Pharmaceuticals
52. How the Western Diet Thwarts the Epigenetic Efforts of Gut Microbes in Ulcerative Colitis and Its Association with Colorectal Cancer
    Avisek Majumder, Shabana Bano · 2024 · Biomolecules
53. Predictors for colectomy in patients with acute severe ulcerative colitis: a systematic review and meta-analysis
    Jieqi Zheng, Zinan Fan, Chao Li, Daiyue Wang, Shenghong Zhang, Rirong Chen · 2024 · BMJ Open Gastroenterology
54. Transient elastography to assess liver stiffness in patients with inflammatory bowel disease
    Berrie Meijer, Charlotte K. van Everdingen, Dewkoemar Ramsoekh, Catherine Ann Malcolm Stedman, CHRISTOPHER M. A. FRAMPTON, Chris Jacob Johan Mulder, Gerd Bouma, Nanne K.H. de Boer, Richard Blair Gearry · 2017 · Digestive and Liver Disease
55. The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFα Treatment in Crohn’s Disease
    Joachim Høg Mortensen, Wouter Tobias van Haaften, M.A. Karsdal, Anne‐Christine Bay‐Jensen, Peter Olinga, Henning Grønbæk, Christian Lodberg Hvas, Tina Manon‐Jensen, Gerard D. H. Dijkstra, Anders Kirch Dige · 2020 · Journal of Clinical Gastroenterology
56. Update on therapeutic management of spondyloarthritis associated with inflammatory bowel disease
    Dorra Ben Nessib, Hanène Lassoued Ferjani, Kaouther Maatallah, Safa Rahmouni, Dhia Kaffel, Wafa Hamdi · 2020 · Clinical Rheumatology
57. Therapeutic drug monitoring of anti-tumor necrosis factor agents: lessons learned and remaining issues
    Zhigang Wang, Erwin Dreesen · 2020 · Current Opinion in Pharmacology
58. Factors influencing the outcome of vedolizumab treatment: Real‐life data with objective outcome measurements
    Orla Mader, Pascal Juillerat, Luc Biedermann, Pierre Michetti, Petr L. Hruz, Valerie E. H. Pittet, Gerhard Rogler, Nadine Zahnd, Frank Seibold · 2020 · United European Gastroenterology Journal
59. The Degree of Ulcerative Colitis Burden of Luminal Inflammation score is superior to predicting medium- to long-term prognosis in patients with active ulcerative colitis
    Liang Chen, Jiaolan Yang, Leilei Fang, Wei Hua Wu, Baisui Feng, Yanhong Shi, Mingming Sun, Xiaomin Sun, Zhanju Liu · 2020 · Therapeutic Advances in Gastroenterology
60. Human Cytomegalovirus and Epstein-Barr virus specific immunity in patients with ulcerative colitis
    Rachele Ciccocioppo, Caterina Mengoli, E. Betti, Giuditta Comolli, Irene Cassaniti, Antonio Piralla, Peter Kružliak, Martin Čaprnda, Lodovica Pozzi, Gino Roberto Corazza et al. · 2021 · Clinical and Experimental Medicine
61. Mining the Microbiome and Microbiota-Derived Molecules in Inflammatory Bowel Disease
    Matthijs Bekkers, Bojan Stojkovic, Gerard E. Kaiko · 2021 · International Journal of Molecular Sciences
62. Analysis of the initial dose and reduction rate of corticosteroid for ulcerative colitis in clinical practice
    Masataka Masuda, Norimasa Fukata, Yasuki Sano, Shuhei Nishimon, Mamiko Aoi, Takashi Tomiyama, Toshiro Fukui, Mika Omiya, Kazuichi Okazaki, Makoto Naganuma · 2022 · JGH Open
63. Practice Variations in the Management of Inflammatory Bowel Disease Between Pediatric and Adult Gastroenterologists
    Amit Assa, Irit Avni, Ofer Ben‐Bassat, Yaron Niv, Raanan Shamir · 2015 · Journal of Pediatric Gastroenterology and Nutrition
64. When to Start Immunomodulators in Inflammatory Bowel Disease?
    Ala I. Sharara · 2016 · Digestive Diseases
65. Use of biologics and chemotherapy in patints with inflammatory bowel diseases and cancer
    Aranzazu Jauregui-Amezaga · 2016 · Annals of Gastroenterology
66. Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: A global survey of physicians' practice
    Shomron Ben‐Horin, Jane Mary Andrews, Konstantinos H Katsanos, Florian Rieder, Flávio Steinwurz, Konstantinos Κarmiris, Jae Hee Cheon, Gordon William Moran, Monica Cesarini, Christian D. Stone et al. · 2017 · World Journal of Gastroenterology
67. Styrene maleic acid encapsulated raloxifene micelles for management of inflammatory bowel disease
    Khaled F. Greish, Safa Taha, Anfal A. Jasim, Sara Abdelghany, Ameera Sultan, Ali Alkhateeb, Manal Ahmed Othman, Fang Jun, Sébastien Taurin, Moiz Bakhiet · 2017 · Clinical and Translational Medicine
68. Real World Effectiveness of Golimumab Therapy in Ulcerative Colitis Regardless of Prior TNF Exposure
    Brian L. Bressler, Martin Williamson, Bernie D. Sattin, Fernando Camacho, A. Hillary Steinhart · 2018 · Journal of the Canadian Association of Gastroenterology
69. Impact of age at diagnosis on natural history of patients with elderly-onset ulcerative colitis: A French population-based study
    Dana Ďuricová, Benjamin Pariente, Hélène Sarter, Mathurin Fuméry, Ariane Leroyer, Cloé Charpentier, Laura Armengol‐Debeir, Laurent Peyrin‐Biroulet, Guillaume Savoye, Corinne Gower‐Rousseau · 2018 · Digestive and Liver Disease
70. The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis
    Bruce E. Sands, Adam S. Cheifetz, Chudy I. Nduaka, Daniel Quirk, Wenjin Wang, Eric Maller, Gary S. Friedman, Chinyu G. Su, Peter Higgins · 2019 · Journal of Crohn s and Colitis
71. Comparison of small-bowel colon capsule endoscopy system to conventional colonoscopy for the evaluation of ulcerative colitis activity
    Samuel Nathan Adler, Yago González Lama, Virginia Matallana Royo, Cristina Suárez Ferrer, Avraham Schwartz, Ariella Bar‐Gil Shitrit · 2019 · Endoscopy International Open
72. Chemical hybridization of sulfasalazine and dihydroartemisinin promotes brain tumor cell death
    Annemarie Ackermann, Aysun Çapcı, Michael Buchfelder, Svetlana B. Tsogoeva, Nicolai E. Savaskan · 2021 · Scientific Reports
73. Maintaining infliximab induced clinical remission with azathioprine and 5-aminosalicylates in acute severe steroid-refractory ulcerative colitis has lower cost and high efficacy (MIRACLE): a multicenter study
    Ramit Mahajan, Arshdeep Singh, Saurabh Kedia, Kirandeep Kaur, Vandana Midha, Pabitra Sahu, Varun Mehta, Dharmatma Singh, Namita Bansal, Khushdeep Dharni et al. · 2021 · Intestinal Research
74. Fulminant ulcerative colitis in a healthy pregnant woman
    Rossana Orabona, A. Valcamonico, Marianna Salemme, Stefania Manenti, Guido AM Tiberio, Tiziana Frusca · 2015 · World Journal of Gastroenterology
75. Gastrointestinal disease
    Lauren Beswick, William W. Kemp · 2015
76. An Extremes of Phenotype Approach Confirms Significant Genetic Heterogeneity in Patients with Ulcerative Colitis
    Mortlock, Sally, Lord, Anton, Montgomery, Grant, Zakrzewski, Martha, Simms, Lisa A, Krishnaprasad, Krupa, Hanigan, Katherine, Doecke, James D, Walsh, Alissa, Lawrance, Ian C et al. · 2023 · Journal of Crohn's and Colitis
77. Real-World Effectiveness of Vedolizumab Dose Escalation in Patients With Inflammatory Bowel Disease: A Systematic Literature Review
    Dipen A. Patel, Stéphan Martin, Michelle Luo, Lyann Ursos, Richard A. Lirio, Pravin Kamble, Song Wang · 2022 · Crohn s & Colitis 360
78. Management of Inflammatory Bowel Disease in Patients with Current or Past Malignancy
    Florian Poullenot, David Laharie · 2023 · Cancers
79. Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study
    Silvio Danese, Ailsa L Hart, Axel U Dignass, Edouard J. Louis, Geert D’Haens, Iris Dotan, Gerhard Rogler, Laurence D’Agay, Claudio Iannacone, Laurent Peyrin‐Biroulet · 2016 · BMJ Open Gastroenterology
80. What is the real-life maintenance mesalazine dose in ulcerative colitis?
    Alicia Algaba, Iván Guerra, Ana García García de Paredes, María Hernández Tejero, Carlos Ferré, Daniel Bonillo, Lara Aguilera, Antonio López–Sanromán, Fernando Bermejo · 2016 · Revista Española de Enfermedades Digestivas
81. Bone Mass Development from Childhood into Young Adulthood in Patients with Childhood-onset Inflammatory Bowel Disease
    Gudmundur Vignir Sigurdsson, Susanne Schmidt, Dan Mellström, Claes Ohlsson, Jenny M. Kindblom, Mattias Lorentzon, Robert Saalman · 2017 · Inflammatory Bowel Diseases
82. Costs of dose escalation among ulcerative colitis patients treated with adalimumab in Germany
    Bernadette Poellinger, Wolfgang Schmidt, Anna Seiffert, Heidi Imhoff, Martin Emmert · 2018 · The European Journal of Health Economics
83. Solving the questions regarding 5-aminosalitylate formulation in the treatment of ulcerative colitis
    Makoto Naganuma · 2020 · Journal of Gastroenterology
84. Background and Evaluation of Hypercoagulability.
    William J Sandborn, Brian G Feagan, Hanauer Sb, Gary R. Lichtenstein · 2021 · PubMed Central
85. Are Steroids Still Useful in Immunosuppressed Patients With Inflammatory Bowel Disease? A Retrospective, Population-Based Study
    Beatriz Sicilia, Lara Arias, Gadea Hontoria, Nieves García, Ester Badía, Fernando Gomollón · 2021 · Frontiers in Medicine
86. When disease extent is not always a key parameter: Management of refractory ulcerative proctitis
    Georgios Michalopoulos, Konstantinos Κarmiris · 2021 · Current Research in Pharmacology and Drug Discovery
87. Utilization of Colonoscopy Following Treatment Initiation in U.S. Commercially Insured Patients With Inflammatory Bowel Disease, 2013-2019
    Jeff Y. Yang, Jennifer Leigh Lund, Virginia Pate, Michael D. Kappelman · 2022 · Inflammatory Bowel Diseases
88. Vedolizumab for the treatment of ulcerative colitis
    Andreas Stallmach, Carsten Schmidt, Niels Teich · 2015 · Expert Review of Gastroenterology & Hepatology
89. The prevalence and clinical characteristics of anemia in Korean patients with inflammatory bowel disease
    Dae Sung Lee, Ki Bae Bang, Ji‐Yeon Kim, Yoon Suk Jung, Jung Ho Park, Hong Joo Kim, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim et al. · 2016 · Intestinal Research
90. The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort
    Marianne Rebecca Spalinger, Marius Vögelin, Luc Biedermann, Jonas Zeitz, Jean‐Benoît Rossel, Michael Christian Sulz, Pascal Frei, Sylvie Scharl, Stephan R. Vavricka, Michael Fried et al. · 2016 · Digestion
91. Assessment of disease‐related knowledge and possible factors associated with the knowledge level among Chilean patients with inflammatory bowel disease
    Daniela Simian, Lilian Flores, Rodrigo Quera, Udo Kronberg, Patricio Ibáñez L, Carolina Figueroa, Jaime Lubascher · 2016 · Journal of Clinical Nursing
92. How I treat my inflammatory bowel disease-patients with thiopurines?
    Berrie Meijer, Chris Jacob Johan Mulder, Adriaan Anthonie Van Bodegraven, Nanne K.H. de Boer · 2016 · World Journal of Gastrointestinal Pharmacology and Therapeutics
93. Predictors of quality-of-life after ileal pouch-anal anastomosis in patients with ulcerative colitis
    Sherif M Abolfotouh, Tero Rautio, Kai Klintrup, Ilona Helavirta, Jyrki Tapani Mäkelä · 2017 · Scandinavian Journal of Gastroenterology
94. Value of upper endoscopic biopsies in predicting medical refractoriness in pediatric patients with ulcerative colitis
    Katrina Sullivan, Mike Wei, Elizabeth Chernetsova, Soufiane El Hallani, Joseph de Nanassy, Eric Ian Benchimol, David R. Mack, Ahmed Nasr, Dina El Demellawy · 2017 · Human Pathology
95. Surgery versus surveillance in ulcerative colitis patients with endoscopically invisible low-grade dysplasia: a cost-effectiveness analysis
    Ben Parker, James P. Buchanan, Sarah Wordsworth, Satish Keshav, Bruce D. George, James Edward East · 2017 · Gastrointestinal Endoscopy
96. Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study
    Daniela Pugliese, Annalisa Aratari, Stefano Festa, Pietro Manuel Ferraro, Rita Monterubbianesi, Luisa Guidi, Maria Lia Scribano, Claudio Papi, Alessandro Armuzzi · 2018 · Gastroenterology Research and Practice
97. Validation of US evaluation of ulcerative colitis activity
    Satomi Omotehara, Mutsumi Nishida, Kenji Kinoshita, Reizo Onishi, Aki Onodera, Mitsuhisa Suya, Toru Hasegawa, Daiki Mitsumori, Takehiko Katsurada, Takanori Teshima · 2019 · Ultrasound in Medicine & Biology
98. NGS study of glucocorticoids response genes in inflammatory bowel disease patients
    Marzena Skrzypczak-Zielińska, Marcin Gabryel, Daria Marszalek, Agnieszka Dobrowolska, Ryszard Słomski · 2019 · Archives of Medical Science
99. Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis
    Lorenzo Bertani, Giorgia Bodini, Maria Gloria Mumolo, Nicola de Bortoli, Linda Ceccarelli, Leonardo Frazzoni, Gherardo Tapete, Eleonora Albano, Maria Corina Plaz Torres, Massimo Bellini et al. · 2019 · Digestive Diseases and Sciences
100. Exposure‐Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies
     Arnab Mukherjee, Shinichi Tsuchiwata, Timothy Nicholas, Jack Cook, Irene Modesto, Chinyu G. Su, Geert D’Haens, William J. Sandborn · 2022 · Clinical Pharmacology & Therapeutics